RenovoRx initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst Scott Henry initiated coverage of RenovoRx with a Buy rating and $4 price target. RenovoRx’s developmental RenovoGem for the treatment of pancreatic cancer can pass pivotal trials, be approved by the FDA, and drive revenues and ultimately profits to the company, the analyst tells investors in a research note. The firm says the key share catalyst is the second interim analysis for the TIGeR-PaC trial expected in Q4.